An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia
Part of paid clinical trials in Oakland, California.
- Sponsor
- BioMarin Pharmaceutical
- Study ID
- NCT03424018
- Phase
- PHASE3
- Status
- Active Not Recruiting
Conditions
- Achondroplasia
Eligibility Criteria
- Sex
- ALL
- Age
- 6 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- BMN 111 — DRUGSubcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.
Study Details
The intent and design of this Phase 3 study is to assess BMN 111 as a therapeutic option for the treatment of children with Achondroplasia
Key Dates
- Start date
- Dec 12, 2017
- Status verified
- Mar 2026
- Primary completion
- Jun 30, 2031
- Completion
- Jun 30, 2031
Study Design
- Enrollment
- 119 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: BMN 111
Primary Outcome Measure
Change from baselines in mean annualized growth velocity [ Time Frame: Through study completion, an average of 1 year ]
Locations (11)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Children's Hospital & Research Center Oakland | Oakland | California | 94609 | - |
| Harbor - UCLA Medical Center | Torrance | California | 90509 | - |
| Alfred I. duPont Hospital for Children | Wilmington | Delaware | 19803 | - |
| Emory University | Atlanta | Georgia | 30322 | - |
| Ann and Robert H. Lurie Children's Hospital of Chicago | Chicago | Illinois | 60611 | - |
| Johns Hopkins University | Baltimore | Maryland | 21287 | - |
| University of Missouri | Columbia | Missouri | 65201 | - |
| Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio | 45229 | - |
| Baylor College of Medicine | Houston | Texas | 77030 | - |
| Seattle Children's Hospital | Seattle | Washington | 98105 | - |
| Medical College of Wisconsin, Children's Hospital | Milwaukee | Wisconsin | 53226 | - |
Find similar trials in Oakland, CA
By research site
Related Studies
- Achondroplasia Natural History Multicenter Clinical StudyRecruiting · Johns Hopkins University · Baltimore, Maryland
- Extension Study of Infigratinib in Children With Achondroplasia (ACH)PHASE2 · Enrolling By Invitation · QED Therapeutics, a BridgeBio company · Oakland, California
- A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With AchondroplasiaPHASE2/PHASE3 · Enrolling By Invitation · Ascendis Pharma Growth Disorders A/S · Little Rock, Arkansas
- A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With AchondroplasiaPHASE2 · Recruiting · Ascendis Pharma A/S · Saint Paul, Minnesota